Cross-sectional Study for Identification and Description of Severe Asthma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

767

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Asthma
Interventions
DRUG

Short Acting Beta Agonist (SABA)

Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments

Trial Locations (74)

2450

GSK Investigational Site, Coffs Harbour

10717

GSK Investigational Site, Berlin

12157

GSK Investigational Site, Berlin

12203

GSK Investigational Site, Berlin

13086

GSK Investigational Site, Berlin

13331

GSK Investigational Site, Marseille

13597

GSK Investigational Site, Berlin

14830

GSK Investigational Site, Corning

15241

GSK Investigational Site, Pittsburgh

21033

GSK Investigational Site, Dijon

21044

GSK Investigational Site, Columbia

21236

GSK Investigational Site, Baltimore

22299

GSK Investigational Site, Hamburg

23552

GSK Investigational Site, Lübeck

24837

GSK Investigational Site, Schleswig

28150

GSK Investigational Site, Shelby

28277

GSK Investigational Site, Charlotte

29615

GSK Investigational Site, Greenville

32308

GSK Investigational Site, Tallahassee

33604

GSK Investigational Site, Pessac

38043

GSK Investigational Site, Grenoble

42301

GSK Investigational Site, Owensboro

44093

GSK Investigational Site, Nantes

44277

GSK Investigational Site, Nantes

45231

GSK Investigational Site, Cincinnati

51092

GSK Investigational Site, Reims

55402

GSK Investigational Site, Minneapolis

55441

GSK Investigational Site, Plymouth

59037

GSK Investigational Site, Lille

64109

GSK Investigational Site, Bayonne

65013

GSK Investigational Site, Tarbes

67091

GSK Investigational Site, Strasbourg

69317

GSK Investigational Site, Lyon

69655

GSK Investigational Site, Villefranche-sur-Saône

72205

GSK Investigational Site, Little Rock

75877

GSK Investigational Site, Paris

76031

GSK Investigational Site, Rouen

80539

GSK Investigational Site, Munich

82131

GSK Investigational Site, Gauting

90025

GSK Investigational Site, Los Angeles

90274

GSK Investigational Site, Rolling Hills Estates

91786

GSK Investigational Site, Upland

92123

GSK Investigational Site, San Diego

92506

GSK Investigational Site, Riverside

92663

GSK Investigational Site, Newport Beach

93720

GSK Investigational Site, Fresno

97504

GSK Investigational Site, Medford

T8H 0N2

GSK Investigational Site, Sherwood Park

L6T 0G1

GSK Investigational Site, Brampton

L7N 3V2

GSK Investigational Site, Burlington

L3M1P3

GSK Investigational Site, Grimsby

N6A1V2

GSK Investigational Site, London

L5A 3V4

GSK Investigational Site, Mississauga

J6E 2B4

GSK Investigational Site, St-Charles-Borromée

M5G 1E2

GSK Investigational Site, Toronto

M5T 3A9

GSK Investigational Site, Toronto

N8X2G1

GSK Investigational Site, Windsor

H4J 1C5

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Québec

G1V 4M6

GSK Investigational Site, Québec

G8T 7A1

GSK Investigational Site, Trois-Rivières

03050

GSK Investigational Site, Cottbus

04103

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig

B15 2WB

GSK Investigational Site, Birmingham

B18 7QH

GSK Investigational Site, Birmingham

CB2 2XY

GSK Investigational Site, Cambridge

RH10 7DX

GSK Investigational Site, Crawley

L12 2AP

GSK Investigational Site, Liverpool

SW17 0RE

GSK Investigational Site, London

TS4 3BW

GSK Investigational Site, Middlesbrough

BA3 2UH

GSK Investigational Site, Radstock, Bath

M6 8HD

GSK Investigational Site, Salford

BA14 9AR

GSK Investigational Site, Trowbridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02293265 - Cross-sectional Study for Identification and Description of Severe Asthma Patients | Biotech Hunter | Biotech Hunter